Drilldown/Medicines
Medicines > classes 
:
Benzodiazepine or
Tryptamine or
[[:Category:Anti-inflammatories|Anti-inflammatory]]
:
Benzodiazepine or
Tryptamine or
[[:Category:Anti-inflammatories|Anti-inflammatory]] Use the filters below to narrow your results.
generic:
brand:
None (35) ·
Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1) ·
Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular) (1) ·
Dalmane (1) ·
Doral (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Onfi (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Tranxene (1) ·
Versed (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1)
uses:
None (48) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1) ·
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)
starting dose:
None (48) ·
0.25 mg (1) ·
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) ·
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)
preparations:
None (48) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
0.6 mg tablets; 0.6 mg/5 mL solution; 0.5 mg tablets (Lodoco) (1) ·
Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (48) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 51 results in range #1 to #51.